Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|June 5, 2026

The BioPharm Brief: Biosimilars, Stem Cells, and Checkpoints

In this episode of The BioPharm Brief, we cover the FDA approval of Lupin's interchangeable ranibizumab biosimilar Ranluspec, a new iPSC cell therapy manufacturing partnership between Made Scientific and Pluristyx, and emerging research on TIGIT as a potential immunotherapy target in pancreatic cancer.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today's briefing highlights progress in biosimilars, cell therapy manufacturing, and cancer immunotherapy, underscoring how companies and researchers are working to expand patient access, streamline development, and tackle some of oncology's toughest challenges.

First, Lupin announced that the FDA has approved Ranluspec, an interchangeable biosimilar to Lucentis, for multiple retinal diseases. The product is approved in both vial and prefilled syringe presentations and covers indications including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion-related macular edema. The approval adds another competitor to the ophthalmology biosimilars market and reflects continued momentum in efforts to improve access to high-cost biologic therapies.

Next, cell therapy manufacturing received a boost through a new partnership between Made Scientific and Pluristyx. The companies plan to integrate Pluristyx's clinical-grade induced pluripotent stem cell, or iPSC, technologies into Made Scientific's development and manufacturing services. The goal is to provide developers with a more streamlined path from starting cell lines through clinical and commercial production, potentially reducing development timelines and manufacturing complexity for next generation cell therapies.

Finally, a newly published review examined TIGIT, an immune checkpoint target that continues to attract attention despite mixed clinical results. Researchers highlighted TIGIT's role in regulating antitumor immune responses and discussed its potential relevance in pancreatic cancer, a disease where immunotherapy has historically delivered limited benefit. The review emphasizes that important questions remain regarding patient selection, biomarkers, combination strategies, and whether TIGIT inhibition can generate meaningful clinical benefit in difficult-to-treat solid tumors.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • Ranluspec approved: FDA approval of Lupin's interchangeable ranibizumab biosimilar expands competition in the retinal disease market.
  • iPSC partnership launched: Made Scientific and Pluristyx aim to streamline development and manufacturing for iPSC-derived cell therapies.
  • TIGIT questions remain: New research highlights TIGIT's potential in cancer immunotherapy, but clinical validation is still needed.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more